Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017 (2017), Article ID 8391637, 8 pages
https://doi.org/10.1155/2017/8391637
Research Article

Modified Suanzaorentang Had the Treatment Effect for Generalized Anxiety Disorder for the First 4 Weeks of Paroxetine Medication: A Pragmatic Randomized Controlled Study

1Internal Medicine of Traditional Chinese Medicine, The 2nd Clinical Medical College, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou, Zhejiang 310053, China
2Molecular Biology Laboratory, Hangzhou Seventh People’s Hospital, 305 Tianmushan Road, Hangzhou, Zhejiang 310013, China
3Psychosomatic Disorders Department, Hangzhou Seventh People’s Hospital, 305 Tianmushan Road, Hangzhou, Zhejiang 310013, China

Correspondence should be addressed to Yong-Hua Zhang; moc.361@61961hyz

Received 2 February 2017; Revised 17 March 2017; Accepted 6 April 2017; Published 3 May 2017

Academic Editor: Haroon Khan

Copyright © 2017 Ming-Fen Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Paroxetine does not show satisfactory therapeutic effect for generalized anxiety disorder (GAD) patients for the first 2–4 weeks of medication. Diazepam is always concurrently used although it has some shortcomings such as physical dependence and withdrawal reactions. In this study, we aimed to identify whether modified Suanzaorentang (MSZRT), a combined Chinese formula including Suanzaorentang (SZRT) and Zhizichitang (ZZCT), could control the anxiety of GAD for the first 4 weeks of paroxetine medication. Methods. 156 GAD patients were randomized to the treatment of paroxetine, paroxetine-diazepam, or paroxetine-MSZRT for 4 weeks. Hamilton Anxiety Scale (HAMA) Test and Self-Rating Anxiety Scale (SAS) Test were determined each week as the evaluation of clinical efficacy. Adverse events (AEs) were also closely observed by performing the Treatment Emergent Symptom Scale (TESS) Test. Results. Both paroxetine-MSZRT and paroxetine-diazepam decreased more HAMA and SAS total scores than paroxetine from weeks 1 to 3. Paroxetine-MSZRT as well as paroxetine-diazepam had an obviously higher onset rate than paroxetine in each week. After 4 weeks’ treatment, the overall effectiveness rate in the paroxetine-MSZRT group (90.00%) was obviously higher than those of the paroxetine group (74.42%) but did not significantly differ from the paroxetine-diazepam group (93.88%). Conclusion. MSZRT had the treatment effect for GAD when paroxetine was used for the first 4 weeks.